A study of reported factor VIII use around the world

Haemophilia

Volumn 16, Issue 1, 2010, Pages 33-46

  Stonebraker, J S ^a   BRooker, M ^b   Amand, R E ^c   Farrugia, A ^d   Srivastava, A ^e  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b WORLD FEDERATION OF HEMOPHILIA   (Canada)

^c Biotherapeutic Modeling Group Inc   (United States)

^d Plasma Protein Therapeutics Association   (United States)

^e CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Economics; Factor VIII (FVIII) use; FVIII concentrate; Haemophilia A; National healthcare planning; Production planning; World Federation of Hemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ARTICLE; DEVELOPED COUNTRY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG UTILIZATION; ECONOMIC EVALUATION; HEALTH CARE FINANCING; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH ECONOMICS; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; RESOURCE ALLOCATION; SOCIOECONOMICS; TREND STUDY;

DELIVERY OF HEALTH CARE; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG UTILIZATION; FACTOR VIII; HEMOPHILIA A; HUMANS; INCOME; WORLD HEALTH;

EID: 73949094250     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02131.x     Document Type: Article

References (65)

1. Evatt BL. Demographics of hemophilia in developing countries. Sem Thromb Hemostasis 2005, 31:489-94.
2. Aledort LM. Unsolved problems in haemophilia. Haemophilia 1998, 4:341-5.
3. Lee CA. Towards achieving global haemophilia care - World Federation of Hemophilia programmes. Haemophilia 1998, 4:463-73.
4. Isarangkura P. Haemophilia care in the developing world: benchmarking for excellence. Haemophilia 2002, 8:205-10.
5. Ikkala E, Helske T, Myllylä, Nevanlinna HR, Pitkänen P, Rasi V. Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930-79. Br J Haematol 1982, 52:7-12.
6. Larsson SA. Life expectancy of Swedish haemophiliacs, 1831-1980. Br J Haemotol 1985, 59:593-602.
7. Skinner MW. Treatment for all: a vision for the future. Haemophilia 2006, 12(Suppl 3):169-73.
8. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998, 4:474-80.
9. Windyga J, Lopaciuk S, Stefanska E. Haemophilia in Poland. Haemophilia 2006, 12:52-7.
10. Zhang L, Li H, Zhao H, Zhang X, Li L, Yang R. Retrospective analysis of 1,312 patients with haemophilia and related disorders in a single Chinese institute. Haemophilia 2003, 9:696-702.
11. Jones P. Haemophilia: a global challenge. Haemophilia 1995, 1:11-13.
12. O'Mahony B, Black C. Expanding hemophilia care in developing countries. Sem Thromb Hemostasis 2005, 31:561-8.
13. Ayob Y. Management of hemophilia in resource-limited countries. Transf Alt Transf Med 2008, 10:70-4.
14. Bolton-Maggs PHB. Optimal haemophilia care versus the reality. Br J Haematol 2005, 132:671-82.
15. Evatt BL. The natural evolution of haemophilia care: developing and sustaining comprehensive care globally. Haemophilia 2006, 12(Suppl 3):13-21.
16. Poon M-C, Luke K-H. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities. Haemophilia 2008, 14:879-88.
17. Skinner MW. WFH - the cornerstone of global development: 45 years of progress. Haemophilia 2008, 14(Suppl 3):1-9.
18. Srivastava A. Factor replacement therapy in haemophilia - are there models for developing countries? Haemophilia 2003, 9:391-6.
19. Tezanos Pinto M, Ortiz Z. Haemophilia in the developing world: successes, frustrations and opportunities. Haemophilia 2004, 10(Suppl 4):14-9.
20. Schramm W, Berger K. Economics of prophylaxis treatment. Haemophilia 2003, 9(Suppl 1):111-6.
21. Antunes SV. Haemophilia in the developing world: the Brazilian experience. Haemophilia 2002, 8:199-204.
22. Evatt BL, Robillard L. Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism. Haemophilia 2000, 6:131-4.
23. Kar A, Potnis-Lele M. Descriptive epidemiology of haemophilia in Maharashtra, India. Haemophilia 2001, 7:561-7.
24. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001, 7:117-22.
25. Bohn RL, Schramm W, Bullinger M, Van den Berg M, Blanchette V. Outcome measures in haemophilia: more than just factor levels. Haemophilia 2004, 10(Suppl 1):2-8.
26. Evatt BL. Observations from Global Survey 2001: an emerging database for progress. Haemophilia 2002, 8:153-6.
27. Farrugia A. Safety and supply of hemophilia products: worldwide perspectives. Haemophilia 2004, 10:327-33.
28. O'Mahony B. WFH: back to the future. Haemophilia 2004, 10(Suppl 4):1-8.
29. Shapiro AD. A global view on prophylaxis: possibilities and consequences. Haemophilia 2003, 9(Suppl 1):10-8.
30. Stonebraker JS, Amand RE, Nagle AJ. A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community. Haemophilia 2003, 9:245-50.
31. World Development Indicators 2007 2007, http://www.worldbank.org, (), Washington, DC, World Bank
32. The OECD 2008, http://www.oecd.org, (), Paris, France, OECD
33. The Plasma Fractions Market in the Middle East - 2003 2004, Orange, CT
34. The Plasma Fractions Market in Central and South America - 2004 2005, Volumes A and B, Orange, CT
35. The Plasma Fractions Market in Europe - 2005 2006, Orange, CT
36. The Plasma Fractions Market in the United States - 2006 2007, Orange, CT
37. The Plasma Fractions Market in Asia and Pacific - 2006 2007, Orange, CT
38. Report on the WFH Global Survey 2002 2002, Montreal, Canada, WFH
39. Report on the WFH Global Survey 2003 2004, Montreal, Canada, WFH
40. Report on the Annual Global Survey 2004 2005, Montreal, Canada, WFH
41. Report on the Annual Global Survey 2005 2006, Montreal, Canada, WFH
42. Report on the Annual Global Survey 2006 2007, Montreal, Canada, WFH
43. Jones P, Robillard L. The World Federation of Hemophilia: 40 years of improving haemophilia care worldwide. Haemophlilia 2003, 9:663-9.
44. World Population Prospects: The 2006 Revision and World Urbanization Prospects: The 2005 Revision 2006, http://esa.un.org/unpp, New York, NY, UN
45. WFH Global Survey on Hemophilia 1999 edition 1999, Montreal, Canada, WFH
46. WFH Global Survey on Hemophilia 2000 edition 2000, Montreal, Canada, WFH
47. Report on the WFH Global Survey 2001 2001, Montreal, Canada, WFH
48. Stonebraker JS, Bolton-Maggs PHB, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia
49. Helgason A, Nicholson G, Stefansson K, Donnelly P. A reassessment of genetic diversity in icelanders: strong evidence from multiple loci for relative homogeneity caused by genetic drift. Ann Hum Genetics 2003, 67:281-97.
50. Karimi M, Yarmohammadi H, Ardeshiri R, Yarmohammadi H. Inherited coagulation disorders in southern Iran. Haemophilia 2002, 8:740-4.
51. Ziaei JE, Dolatkhah R, Dastgiri S. Inherited coagulation disorders in the northwestern region of Iran. Haemophilia 2005, 11:424-6.
52. Mehdizadeh M, Kardoost M, Zamani G, Baghaeepour MR, Sadeghian K, Pourhoseingholi MA. Occurrence of haemophilia in Iran. Haemophilia 2009, 15:348-51.
53. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. Am J Hematol 1998, 59:288-94.
54. Nilsson IM. Management of haemophilia in Sweden. Thromb Haemostasis 1976, 35:510-21.
55. Australian Health Ministers' Advisory Council Blood and Blood Products Committee Report of the working party on the supply and use of Factor VIII and Factor IX in Australia. 2003, http://www.nba.gov.au/pubs/pdf/factor-viii-ix.pdf, On
56. Government response to the Senate Inquiry into Hepatitis C and the Blood Supply. 2004, http://www.health.gov.au/internet/ministers/publishing.nsf/650f3eec0dfb990fca25692100069854/5180d4f9ab576ff4ca2570120024bf2e?OpenDocument, On
57. Schramm W, Szucs TD. State-of-the-art principles and practices of medical economics. Haemophilia 1998, 4:491-7.
58. Ananyeva N, Khrenov A, Darr F, Summers R, Sarafanov A, Saenko E. Treating haemophilia A with recombinant blood factors: a comparison. Expert Opin Pharmacother 2004, 5:1061-70.
59. Diebold FX. Elements of Forecasting 2001, 2nd edn, South-Western, Cincinnati, OH
60. Linton JD. Determining demand, supply, and pricing for emerging markets based on disruptive process technologies. Technol Forecast Social Change 2004, 71:105-20.
61. Ludlam CA, Lee RJ, Prescott RJ. Haemophilia care in central Scotland 1980-94. I. Demographic characteristics, hospital admissions and causes of death. Haemophilia 2000, 6:494-503.
62. Stonebraker JS, Amand RE, Bauman MV, Nagle AJ, Larson PJ. Modelling haemophilia epidemiology and treatment modalities to estimate unconstrained factor VIII demand. Haemophilia 2004, 10:18-26.
63. Srivastava A, Hoots WK, Soucie JM, Ludlam CA. Linking the world with training and research for improving haemophilia care. Haemophilia 2008, 14(Suppl 3):43-8.
64. WHO confirms hemophilia treatment products as 'essential medicines'. 2006, http://www.wfh.org/index.asp?lang=EN, on
65. 2005, http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf, 14th edition (March 2005) Essential Medicines on